Format
Sort by
Items per page

Send to

Choose Destination

Best matches for antipsychotic agents AND brain AND disease progression AND schizophrenia:

Confounders of excessive brain volume loss in schizophrenia. Van Haren NE et al. Neurosci Biobehav Rev. (2013)

Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Shepherd AM et al. Neurosci Biobehav Rev. (2012)

Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries. Davis J et al. Aust N Z J Psychiatry. (2014)

Search results

Items: 1 to 20 of 89

1.

The treatment of schizophrenia: Can we raise the standard of care?

Catts SV, O'Toole BI.

Aust N Z J Psychiatry. 2016 Dec;50(12):1128-1138. Epub 2016 Nov 7. Review.

PMID:
27821411
2.

Progressive disability and prefrontal shrinkage in schizophrenia patients with poor outcome: A 3-year longitudinal study.

Dusi N, Bellani M, Perlini C, Squarcina L, Marinelli V, Finos L, Altamura CA, Ruggeri M, Brambilla P.

Schizophr Res. 2017 Jan;179:104-111. doi: 10.1016/j.schres.2016.09.013. Epub 2016 Sep 10.

PMID:
27624681
3.

Visual working memory deterioration preceding relapse in psychosis.

Hui CL, Li YK, Li AW, Lee EH, Chang WC, Chan SK, Lam SY, Thornton AE, Sham P, Honer WG, Chen EY.

Psychol Med. 2016 Aug;46(11):2435-44. doi: 10.1017/S0033291716000751. Epub 2016 Jun 16.

PMID:
27305830
4.

Biomarkers for drug development in early psychosis: Current issues and promising directions.

Goff DC, Romero K, Paul J, Mercedes Perez-Rodriguez M, Crandall D, Potkin SG.

Eur Neuropsychopharmacol. 2016 Jun;26(6):923-37. doi: 10.1016/j.euroneuro.2016.01.009. Epub 2016 Mar 19. Review.

5.

Treatment resistant schizophrenia: Course of brain structure and function.

Harvey PD, Rosenthal JB.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Oct 3;70:111-6. doi: 10.1016/j.pnpbp.2016.02.008. Epub 2016 Feb 27. Review.

PMID:
26925705
6.

Prefrontal NAA and Glx Levels in Different Stages of Psychotic Disorders: a 3T 1H-MRS Study.

Liemburg E, Sibeijn-Kuiper A, Bais L, Pijnenborg G, Knegtering H, van der Velde J, Opmeer E, de Vos A, Dlabac-De Lange J, Wunderink L, Aleman A.

Sci Rep. 2016 Feb 23;6:21873. doi: 10.1038/srep21873.

7.

A Selective Review of Cerebral Abnormalities in Patients With First-Episode Schizophrenia Before and After Treatment.

Gong Q, Lui S, Sweeney JA.

Am J Psychiatry. 2016 Mar 1;173(3):232-43. doi: 10.1176/appi.ajp.2015.15050641. Epub 2015 Dec 1. Review.

PMID:
26621570
8.

No progressive brain changes during a 1-year follow-up of patients with first-episode psychosis.

Haukvik UK, Hartberg CB, Nerland S, Jørgensen KN, Lange EH, Simonsen C, Nesvåg R, Dale AM, Andreassen OA, Melle I, Agartz I.

Psychol Med. 2016 Feb;46(3):589-98. doi: 10.1017/S003329171500210X. Epub 2015 Nov 3.

PMID:
26526001
9.

Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy.

Hoosain FG, Choonara YE, Tomar LK, Kumar P, Tyagi C, du Toit LC, Pillay V.

Biomed Res Int. 2015;2015:484963. doi: 10.1155/2015/484963. Epub 2015 Sep 27. Review.

10.

Inflammation in schizophrenia: A question of balance.

Leza JC, García-Bueno B, Bioque M, Arango C, Parellada M, Do K, O'Donnell P, Bernardo M.

Neurosci Biobehav Rev. 2015 Aug;55:612-26. doi: 10.1016/j.neubiorev.2015.05.014. Epub 2015 Jun 16. Review.

PMID:
26092265
11.

No progression of the alterations in the cortical thickness of individuals with schizophrenia-spectrum disorder: a three-year longitudinal magnetic resonance imaging study of first-episode patients.

Roiz-Santiáñez R, Ortiz-García de la Foz V, Ayesa-Arriola R, Tordesillas-Gutiérrez D, Jorge R, Varela-Gómez N, Suárez-Pinilla P, Córdova-Palomera A, Navasa-Melado JM, Crespo-Facorro B.

Psychol Med. 2015 Oct;45(13):2861-71. doi: 10.1017/S0033291715000811. Epub 2015 May 25.

PMID:
26004991
12.

Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development.

Möller M, Swanepoel T, Harvey BH.

ACS Chem Neurosci. 2015 Jul 15;6(7):987-1016. doi: 10.1021/cn5003368. Epub 2015 Apr 2. Review.

PMID:
25794269
13.

N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients.

Zong X, Hu M, Li Z, Cao H, He Y, Liao Y, Zhou J, Sang D, Zhao H, Tang J, Lv L, Chen X.

Sci Rep. 2015 Mar 16;5:9109. doi: 10.1038/srep09109.

14.

Reversible magnetic resonance imaging changes in a case of neuroleptic malignant syndrome.

Jain RS, Gupta PK, Gupta ID, Agrawal R, Kumar S, Tejwani S.

Am J Emerg Med. 2015 Aug;33(8):1113.e1-3. doi: 10.1016/j.ajem.2015.01.029. Epub 2015 Jan 21.

PMID:
25769796
15.

Evidence for progressive brain abnormalities in early schizophrenia: a cross-sectional structural and functional connectivity study.

Zhang F, Qiu L, Yuan L, Ma H, Ye R, Yu F, Hu P, Dong Y, Wang K.

Schizophr Res. 2014 Oct;159(1):31-5. doi: 10.1016/j.schres.2014.07.050. Epub 2014 Aug 28.

PMID:
25176348
16.

Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia.

Molina V, Taboada D, Aragüés M, Hernández JA, Sanz-Fuentenebro J.

Schizophr Res. 2014 Sep;158(1-3):223-9. doi: 10.1016/j.schres.2014.06.042. Epub 2014 Aug 1.

PMID:
25088730
17.

Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk.

Cannon TD, Chung Y, He G, Sun D, Jacobson A, van Erp TG, McEwen S, Addington J, Bearden CE, Cadenhead K, Cornblatt B, Mathalon DH, McGlashan T, Perkins D, Jeffries C, Seidman LJ, Tsuang M, Walker E, Woods SW, Heinssen R; North American Prodrome Longitudinal Study Consortium.

Biol Psychiatry. 2015 Jan 15;77(2):147-57. doi: 10.1016/j.biopsych.2014.05.023. Epub 2014 Jun 12.

18.

Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries.

Davis J, Moylan S, Harvey BH, Maes M, Berk M.

Aust N Z J Psychiatry. 2014 Jun;48(6):512-29. doi: 10.1177/0004867414533012. Epub 2014 May 6. Review.

PMID:
24803587
19.

Altered cortical thickness related to clinical severity but not the untreated disease duration in schizophrenia.

Xiao Y, Lui S, Deng W, Yao L, Zhang W, Li S, Wu M, Xie T, He Y, Huang X, Hu J, Bi F, Li T, Gong Q.

Schizophr Bull. 2015 Jan;41(1):201-10. doi: 10.1093/schbul/sbt177. Epub 2013 Dec 18.

20.

White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.

Wang Q, Cheung C, Deng W, Li M, Huang C, Ma X, Wang Y, Jiang L, Sham PC, Collier DA, Gong Q, Chua SE, McAlonan GM, Li T.

Psychol Med. 2013 Nov;43(11):2301-9. doi: 10.1017/S0033291713000238. Epub 2013 Feb 27.

PMID:
23442742

Supplemental Content

Loading ...
Support Center